Skip to main content
ELDN
NASDAQ Life Sciences

Eledon 10-Q: $69.7M Cash and Going-Concern Doubt Ahead of Phase 3 LEGACY

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.41
Mkt Cap
$192.183M
52W Low
$1.35
52W High
$4.49
52W Position info
79% above low
Off High info
46% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ELDN sits 79% above its 52-week low of $1.35.

Summary

Eledon's Q3 10-Q shows a $3.9M net loss propped up by a $17.0M non-cash warrant gain, $69.7M in cash, and an explicit going-concern warning that funding runs short within twelve months — before the Phase 3 LEGACY trial can start.


Key Events · Earnings and Guidance · ELDN

  • Q3 Loss Masked by Warrant Gain

    Net loss was $3.9M ($0.03/share) versus $17.5M ($0.21) a year ago, but only because of a $17.0M non-cash gain from the change in fair value of warrant liabilities; excluding it, the loss was $21.0M.

  • Cash Falls to $69.7M

    Cash, cash equivalents and short-term investments totaled $69.7M at September 30, 2026, down from $133.3M at December 31, 2025, with nine-month operating cash burn of $64.3M.

  • Going-Concern Doubt Disclosed

    Management concluded existing resources will not fund planned operations for the next twelve months, including the Phase 3 kidney trial, and that financing plans do not alleviate substantial doubt.

  • Manufacturing Spend Jumps

    Q3 R&D rose to $17.8M from $15.0M, driven by a $5.1M increase in manufacturing costs for clinical supply ahead of Phase 3 and the planned islet cell trial.


Analysis · ELDN · Life Sciences

A $17.0M non-cash warrant gain flatters the quarter's headline $3.9M net loss; excluding it, the operating loss was $21.0M, up from $17.5M a year ago as manufacturing spend for Phase 3 supply jumped. More important, the 10-Q states plainly that cash of $69.7M — down from $133.3M at year-end — will not fund operations for the next twelve months, and that management's financing plans do not alleviate substantial doubt about going concern. A capital raise is therefore a precondition for starting the ~600-patient Phase 3 LEGACY kidney trial in Q4 2026, making dilution risk the dominant variable for shareholders.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELDN was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.2M. The 52-week trading range was $1.35 to $4.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELDN - Latest Insights

ELDN
Nov 12, 2026, 4:35 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $2.40 info
Change: -$0.0097 (-0.40%) info
Market Cap: $192.183M info
ELDN
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $2.40 info
Change: -$0.0097 (-0.40%) info
Market Cap: $192.183M info
ELDN
Oct 26, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $2.40 info
Change: +$0.0903 (+4%) info
Market Cap: $192.183M info
ELDN
Sep 22, 2026, 1:48 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $2.40 info
Change: -$0.4847 (-17%) info
Market Cap: $192.183M info
ELDN
Aug 13, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $2.40 info
Change: -$1.21 (-34%) info
Market Cap: $192.183M info